SCHEMBL6938848

SCHEMBL6938848

COc1ccc(CNC(=O)c2cc([N+](=O)[O-])ccc2N[C@H]2CC[C@@H](OC(=O)c3ccccc3)CC2)cc1Cl

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
RORC P51449 1/20 0.43
LMNA P02545 2/20 0.42
HPGD P15428 1/20 0.42
CCR5 P51681 1/20 0.42
PDE5A O76074 4/20 0.42
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
EPHX1 P07099 1/20 0.41
GAA P10253 2/20 0.40
CRHBP P24387 1/20 0.40
HTT P42858 1/20 0.40
CRHR2 Q13324 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
AKR1B1 P15121 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6938843 1.00 MAPT (0.44) MAPTL3MBTL1NPSR1RORCLMNA
SCHEMBL6940168 0.93 MAPT (0.46) MAPTL3MBTL1NPSR1LMNACCR5
SCHEMBL6940165 0.93 MAPT (0.46) MAPTL3MBTL1NPSR1LMNACCR5
SCHEMBL6940097 0.91 LMNA (0.46) MAPTL3MBTL1NPSR1LMNAHPGD
SCHEMBL6940094 0.91 LMNA (0.46) MAPTL3MBTL1NPSR1LMNAHPGD
SCHEMBL7369389 0.91 MAPT (0.45) MAPTRORCLMNAHPGDKMT2A
SCHEMBL7369386 0.91 MAPT (0.45) MAPTRORCLMNAHPGDKMT2A
SCHEMBL6941322 0.87 PDE5A (0.52) MAPTL3MBTL1NPSR1RORCPDE5A
SCHEMBL6944497 0.87 PDE5A (0.52) MAPTL3MBTL1NPSR1RORCPDE5A
SCHEMBL6941319 0.87 PDE5A (0.52) MAPTL3MBTL1NPSR1RORCPDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1080069-B1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO (JP) 2003-03-19 EP claimed
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-12-19 US claimed
CN-1305454-A Anthranilic acid derivatives as inhibitors of CGMP phosphodiesterase FUJISAWA PHARMACEUTICAL CO (JP) 2001-07-25 CN claimed
EP-1080069-B1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO (JP) 2003-03-19 EP disclosed
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-12-19 US disclosed
US-6384080-B1 TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-05-07 US disclosed
CN-1305454-A Anthranilic acid derivatives as inhibitors of CGMP phosphodiesterase FUJISAWA PHARMACEUTICAL CO (JP) 2001-07-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase PDE3A, PDE2A, PDE5A MAPT 4706/4885L3MBTL1 4716/4885NPSR1 2833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.